Global Ovarian Cancer Drugs Market 2019-2023

Below are some of the key findings from the ovarian cancer drugs market analysis report

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the report.

Get a FREE sample now! 

Global ovarian cancer drugs industry overview

At present, there are more than 89 phase III clinical trials to evaluate drugs for the treatment of ovarian cancer. Most of these drugs are evaluating combination therapies of the existing drugs. Several companies are developing novel targeted therapies also. This leads to a strong pipeline for the treatment of ovarian cancer, which is one of the critical reasons that will drive the ovarian cancer drugs market’s growth. Researchers are evaluating novel targets such as sphingosine kinase 1 and deubiquitinating enzyme USP7 as recent studies have shown that ovarian cancer can become resistant to PARP inhibitors.

The growing number of research to develop effective combination therapies also assists in the development of a strong pipeline. This will drive the ovarian cancer drugs market to grow at a CAGR of over 22% during the forecast period. Researchers are developing effective combination therapies for disease management by researching the integrated roles of epigenetics, PD-L1 inhibitors, and angiogenesis inhibitors. Rational combination therapy and cell signaling ovarian cancer are also under study for the same purpose.

Top companies covered in the ovarian cancer drugs market research report

The ovarian cancer drugs market is moderately fragmented. Several companies are investing in the development of these drugs. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, the industry analysis report will allow the clients to identify new growth opportunities and design innovative strategies to improve their share in the market.

The report offers a complete analysis of various companies including:

• AstraZeneca
• Clovis Oncology
• F. Hoffmann-La Roche
• Spectrum Pharmaceuticals
• TESARO

Ovarian cancer drugs market segmentation based on geographic regions

• Asia
• Europe
• North America
• ROW

North America will hold the highest market share of the global ovarian cancer drugs market throughout the forecast period. The rising incidence of ovarian cancer, the availability of reimbursement schemes, and new drug approvals for the treatment of ovarian cancer are some of the primary reasons for the high growth of the ovarian cancer drugs market in the region.

Ovarian cancer drugs market segmentation based on the type

• Epithelial ovarian cancer
• Germ cell ovarian cancer
• Stromal cell ovarian cancer
• Small cell ovarian cancer

Epithelial ovarian cancer is the most common type of ovarian cancer. The epithelial ovarian cancer segment will account for the highest share of the ovarian cancer drugs market as it accounts for about 85%-90% of all ovarian neoplasms. Drugs used for epithelial ovarian cancer, both as part of the standard regimen and targeted therapy, are priced high, which contributes significantly to the growth of the segment.

Key highlights of the global ovarian cancer drugs market for the forecast period 2019-2023

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the ovarian cancer drugs market during the next five years
• Precise estimation of the global ovarian cancer drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the industry across various geographies such as Asia, Europe, North America, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details on factors that will challenge the growth of companies